Advice
following a full submission:
aflibercept 40mg/mL solution for injection (Eylea®) is accepted for use within NHS Scotland.
Indication under review: for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).
In a phase III, randomised, sham-controlled study in adults with myopic CNV, aflibercept was statistically superior to sham at improving visual acuity at 24 weeks.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice172KB (PDF)
Medicine details
- Medicine name:
- aflibercept (Eylea)
- SMC ID:
- 1186/16
- Indication:
- for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 October 2016